Compare Natera Inc. Common Stock (NTRA) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Veritone Inc — how do they compare? Natera Inc. Common Stock trades at $392.66 (market cap $57.03B), while Veritone Inc trades at $0.53 (market cap $53.70M). The key difference: Natera Inc. Common Stock is far larger — about 1062× Veritone Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Veritone Inc for 13 Days on average.
| NTRA | VERI | |
|---|---|---|
Market Cap | $57.03B | $53.70M |
Volume | 1,131,157 | 4,439,104 |
Sector | Health | Technology |
52-Week High | $425.64 | $8.39 |
52-Week Low | $179.42 | $0.53 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $56.18B | $89.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Veritone (VERI) trades at $0.59, down 2.64% today, with a bearish technical outlook despite oversold RSI readings. The company shows significant financial challenges with a -117.54% net income margin and consistent quarterly losses, though it maintains a reasonable P/S ratio of 0.5. Recent developments include a $15 million equity offering and new partnerships with ATP Media and ZeroEyes, while facing securities class action litigation.
The stock presents high risk with substantial losses and negative cash flow from operations, though analyst consensus suggests potential upside to $3.75. Investment opportunity exists only for speculative investors betting on AI growth potential, with significant execution and litigation risks weighing on near-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
